arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Centessa Pharmaceuticals plc

CNTA

— Price unavailable

7 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bearish

auto_awesome

Analytical Summary

Centessa Pharmaceuticals plc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -32.9% ↗

FCF / Share $-1.43 ↘

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity 0.21

info Valuation on last close.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$15.00M

— —

Net Income Profit after all expenses

$-197.53M

↑ +16.2% —

FCF / Share Free cash flow per share

$-1.43

↓ -15.3% —

Long-Term Debt Long-term obligations

$110.09M

↑ +1.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	29.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-31.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	32.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	54.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	16.2% Good ↑ Good Improving Year-over-year change in net income	-56.0% Weak ↑ Weak Improving Year-over-year change in net income	30.1% Excellent ↑ Excellent Improving Year-over-year change in net income	43.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-3473.8% Weak Weak Year-over-year change in net income	-110.7% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	-15.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	25.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	22.7% Good Good Year-over-year change in free cash flow	-20.0% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	-0.9% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	14.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.3% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%
FCF / Net Income (x)	0.98x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.36x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.00x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.15x Fair Fair Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-32.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-39.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-62.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-52.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-66.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-30.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-47.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-47.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-59.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-89.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-37.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-350%)	-58.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-491%)	-64.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-526%)	-64.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-529%)	-77.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-617%)	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	0.21x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-65%)	0.27x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-55%)	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.21x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-65%)	0.15x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-74%)	—	—
Interest Coverage (x)	-21.95x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-19.94x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-17.29x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-29.17x Weak Weak Operating income divided by interest expense Optimal: > 5x	-252.25x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$48.80M	$-274.28M	$-128.03M	$-323.84M	$-519.38M	$-7.23M	—
Debt / EBITDA (x)	-0.53x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.54x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.33x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.20x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.11	$0.00	$0.07	$0.00	—	—	—
Basic EPS, GAAP (USD)	$-1.46	$-2.06	$-1.57	$-2.31	$-5.07	—	—
Free Cash Flow per Share (USD)	$-1.43	$-1.24	$-1.67	$-2.16	$-1.80	—	—
Book Value per Share (USD)	$3.53	$3.03	$2.39	$3.54	$5.46	—	—
Tangible Book Value per Share (USD)	$3.53	$3.03	$2.39	$3.54	$5.46	—	—
Basic Weighted Avg Shares (shares)	135.72M	114.47M	96.18M	93.40M	75.17M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$324.94M	$478.41M	$275.71M	$399.41M	$604.14M	$2.55M	—
LT Debt (USD)	$110.09M	$108.94M	$0.00	$69.80M	$75.70M	$0.00	—
Total Equity (USD)	$526.86M	$401.55M	$236.24M	$336.17M	$491.55M	—	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$15.00M	$0.00	$6.85M	$0.00	—	—	—
Depreciation Expense (USD)	$921.00K	$942.00K	$810.00K	$131.00K	$34.00K	$0.00	$6.00K
Net Income, GAAP (USD)	$-197.53M	$-235.76M	$-151.09M	$-216.21M	$-381.07M	$-10.66M	$-5.06M
Operating Cash Flow (USD)	$-193.82M	$-142.06M	$-160.34M	$-200.55M	$-135.11M	$-10.63M	$-5.83M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 25 quarters

Centessa Pharmaceuticals plc

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CNTA with peers